Skip to main content
. 2021 Oct 19;28(3):468–478. doi: 10.1158/1078-0432.CCR-21-2635

Figure 2.

Figure 2. A, Waterfall plot showing objective radiologic response rate to one dose of neoadjuvant nivolumab plus lirilumab in patients with relapsed, resectable SCCHN (RECIST v1.1). B, Viable tumor quantification (%) at the time of salvage surgery following neoadjuvant immunotherapy, arranged by degree of pathologic response (≤50%, partial response; ≤10% major response). HPV, human papillomavirus. C, Preimmunotherapy right posterior tongue biopsy (patient ID #22) showing keratinizing, invasive squamous cell carcinoma (200×; left) and a post-op hemi-glossectomy specimen with extensive fibrosis in the prior tumor bed with an area of necrosis and a few multinucleated giant cells noted in the upper left region (200×; right). D, Tumor and immune cell PD-L1 expression CPS in both the initial preimmunotherapy recurrence specimen and paired salvage tumor specimen, arranged by descending % tumor viability.

A, Waterfall plot showing objective radiologic response rate to one dose of neoadjuvant nivolumab plus lirilumab in patients with relapsed, resectable SCCHN (RECIST v1.1). B, Viable tumor quantification (%) at the time of salvage surgery following neoadjuvant immunotherapy, arranged by degree of pathologic response (≤50%, partial response; ≤10% major response). HPV, human papillomavirus. C, Preimmunotherapy right posterior tongue biopsy (patient ID #22) showing keratinizing, invasive squamous cell carcinoma (200×; left) and a post-op hemi-glossectomy specimen with extensive fibrosis in the prior tumor bed with an area of necrosis and a few multinucleated giant cells noted in the upper left region (200×; right). D, Tumor and immune cell PD-L1 expression CPS in both the initial preimmunotherapy recurrence specimen and paired salvage tumor specimen, arranged by descending % tumor viability.